Bacillus Calmette-Guérin (BCG) vaccine

GPTKB entity

Statements (53)
Predicate Object
gptkbp:instance_of gptkb:vaccine
gptkbp:bfsLayer 5
gptkbp:bfsParent gptkb:Camille_Guérin
gptkbp:appointed_by intradermal injection
gptkbp:average_temperature 2 to 8 degrees Celsius
gptkbp:category live attenuated vaccine
tuberculosis vaccine
oncological vaccine
gptkbp:clinical_trial Phase III
gptkbp:contraindication pregnancy
immunocompromised individuals
gptkbp:defense included in the EPI (Expanded Programme on Immunization)
gptkbp:developed_by gptkb:Camille_Guérin
gptkb:Albert_Calmette
gptkbp:first_introduced gptkb:1921
https://www.w3.org/2000/01/rdf-schema#label Bacillus Calmette-Guérin (BCG) vaccine
gptkbp:is_effective_against reduces severe forms of tuberculosis
variable efficacy against pulmonary tuberculosis
gptkbp:is_used_for bladder cancer treatment
tuberculosis prevention
gptkbp:is_vulnerable_to single dose
preventive vaccine
lower in adults
therapeutic vaccine
may reduce risk of certain cancers
provides some protection against non-tuberculous mycobacterial infections
provides some protection against childhood infections
high in children
may enhance immune response to other vaccines
may reduce risk of Crohn's disease
may reduce risk of allergic diseases
may reduce risk of asthma
may reduce risk of multiple sclerosis
may reduce risk of type 1 diabetes
may reduce risk of ulcerative colitis
multiple doses in some cases
provides some protection against leprosy
reduces incidence of TB
reduces morbidity from TB
reduces mortality from TB
provides some protection against respiratory infections
gptkbp:manager intradermal
gptkbp:marketed_as various brand names
gptkbp:produced_by gptkb:Mycobacterium_bovis
gptkbp:side_effect fever
swelling at injection site
abscess formation
disseminated BCG infection
local skin reaction
lymphadenitis
osteitis
gptkbp:suitable_for infants in high TB prevalence areas
gptkbp:type live attenuated vaccine